Latest filing published 13 Mar 2026 for Sarepta Therapeutics, Inc., €107k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Stephen Mayo is a declared insider at 2 companies (senior executive); the most frequent names are Sarepta Therapeutics, Inc. and Allogene Therapeutics, Inc. The record holds 10 filings, for trades running from 16 November 2021 to 12 March 2026.
No open-market purchase appears, only 4 sales worth €592k. Other entries cover 6 share grants. In 2026 alone, the filings show no purchases and 1 sale.
Most recently, on 13 March 2026, the filings show an open-market sale worth €107k in Sarepta Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations